Rosuvastatin Administration and Its Effect on the IL-6, IL-1β, and TNF-α Cytokines Levels in Peripheral Blood Mononuclear Cells of Type II Diabetes Mellitus Patients with COVID-19
Objective: Patients with cardiovascular disease (CVDs) have been reported to have the potential to experience severe COVID-19. The inflammatory cytokines such as IL-6, IL-1β, and TNF-α are frequently found in the COVID-19 cytokine storm. Because of the pleiotropic effect Rosuvastatin could be useful as an anti-inflammatory drug to suppress cytokine storms for possible COVID-19 therapy. This study aims to study the effect of rosuvastatin administration on IL-6, IL-1β, and TNF-α on peripheral blood mononuclear cells in type 2 diabetes mellitus patients stimulated with the SARS-CoV-2 spike protein. Material and methods: Mononuclear cells were isolated from peripheral venous blood, and then stimulated with the SARS-CoV-2 subunit S1 spike protein and incubated for 24 hours. Cells that had been stimulated by the SARS-CoV-2 spike protein were separated into two groups. Group 1 was the control group, which was not given rosuvastatin. Group 2 was given rosuvastatin at a dose of 20 μM. The expressions of IL-6, IL-1β, and TNF-α were measured from the cell supernatant using the ELISA method. Results: Spike protein stimulation significantly increased the expression of IL-6, IL-1β, and TNF-α (p= 0.37). Rosuvastatin administered at a dose of 20 μM did not significantly decrease IL-6 (p = 0.568) or IL-1β (p = 0.848) expression but increased TNF-α expression (p = 0.792). Conclusion: Rosuvastatin administration did not affect the expression of IL-6, IL-1β, and TNF-α in peripheral blood mononuclear cells of diabetics with stimulation of the SARS-CoV-2 spike protein..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Modern Medicine - 31(2024), 1, Seite 27-35 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ANDRIANTO [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.31689/rmm.2024.31.1.27 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091395208 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091395208 | ||
| 003 | DE-627 | ||
| 005 | 20240414155814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.31689/rmm.2024.31.1.27 |2 doi | |
| 035 | |a (DE-627)DOAJ091395208 | ||
| 035 | |a (DE-599)DOAJdfd0528924b64034bdd6ff0024f5912f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a ANDRIANTO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rosuvastatin Administration and Its Effect on the IL-6, IL-1β, and TNF-α Cytokines Levels in Peripheral Blood Mononuclear Cells of Type II Diabetes Mellitus Patients with COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: Patients with cardiovascular disease (CVDs) have been reported to have the potential to experience severe COVID-19. The inflammatory cytokines such as IL-6, IL-1β, and TNF-α are frequently found in the COVID-19 cytokine storm. Because of the pleiotropic effect Rosuvastatin could be useful as an anti-inflammatory drug to suppress cytokine storms for possible COVID-19 therapy. This study aims to study the effect of rosuvastatin administration on IL-6, IL-1β, and TNF-α on peripheral blood mononuclear cells in type 2 diabetes mellitus patients stimulated with the SARS-CoV-2 spike protein. Material and methods: Mononuclear cells were isolated from peripheral venous blood, and then stimulated with the SARS-CoV-2 subunit S1 spike protein and incubated for 24 hours. Cells that had been stimulated by the SARS-CoV-2 spike protein were separated into two groups. Group 1 was the control group, which was not given rosuvastatin. Group 2 was given rosuvastatin at a dose of 20 μM. The expressions of IL-6, IL-1β, and TNF-α were measured from the cell supernatant using the ELISA method. Results: Spike protein stimulation significantly increased the expression of IL-6, IL-1β, and TNF-α (p= 0.37). Rosuvastatin administered at a dose of 20 μM did not significantly decrease IL-6 (p = 0.568) or IL-1β (p = 0.848) expression but increased TNF-α expression (p = 0.792). Conclusion: Rosuvastatin administration did not affect the expression of IL-6, IL-1β, and TNF-α in peripheral blood mononuclear cells of diabetics with stimulation of the SARS-CoV-2 spike protein. | ||
| 650 | 4 | |a peripheral blood mononuclear cells | |
| 650 | 4 | |a spike protein sars-cov-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a rosuvastatin | |
| 650 | 4 | |a cytokines | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Maya Qurota A’YUN |e verfasserin |4 aut | |
| 700 | 0 | |a I Gde Rurus SURYAWAN |e verfasserin |4 aut | |
| 700 | 0 | |a Fita TRIASTUTI |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Modern Medicine |d Media Med Publicis, 2019 |g 31(2024), 1, Seite 27-35 |w (DE-627)DOAJ000144428 |x 23602473 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:1 |g pages:27-35 |
| 856 | 4 | 0 | |u https://doi.org/10.31689/rmm.2024.31.1.27 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/dfd0528924b64034bdd6ff0024f5912f |z kostenfrei |
| 856 | 4 | 0 | |u https://medicinamoderna.ro/wp-content/uploads/2024/03/Rosuvastatin-Administration-and-Its-Effect-onthe-IL-6-IL-1%CE%B2-and-TNF-%CE%B1-Cytokines-Levels-in-Peripheral-Blood-Mononuclear-Cells-of-Type-II-Diabetes-Mellitus-Patients-with-COVID-19.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1223-0472 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2360-2473 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 1 |h 27-35 | ||